Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.170 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Is It Too Late to Buy Iovance Biotherapeutics Stock?
The stock is down more than 50% from its 52-week high. 
Via The Motley Fool
What's Going On With Iovance Biotherapeutics Today?
On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented... 
Via Benzinga
Iovance Biotherapeutics's Options: A Look at What the Big Money is Thinking
Via Benzinga
How Is The Market Feeling About Iovance Biotherapeutics?
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Top Penny Stocks to Skyrocket Your Wealth in 2024
Find out about the top penny stocks to buy this year for a chance to see incredible results down the road as they soar to new heights. 
Via InvestorPlace
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
New data indicate that its cell therapy could soon find a larger market. 
Via The Motley Fool
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets 
Via News Direct
Exposures Product Safety
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
These biotech stocks have just launched their first products. 
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
4 Small-Cap Value Stocks That Could Go Parabolic
These four small-cap stocks scan as deeply undervalued right now. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns. 
Via InvestorPlace
Why Iovance Stock Is Down 18% Today
Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
IOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024
IOVA stock results show that Iovance Biotherapeutics met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Got $500? These Hot Growth Stocks Are Screaming Buys Right Now
The time to jump into a red-hot growth prospect is usually right now...before any more investors identify the opportunity. 
Via The Motley Fool
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
Is this rising healthcare stock a good buy right now? 
Via The Motley Fool
The Top 3 Biotech Stocks to Buy in April 2024
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential. 
Via The Motley Fool
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.